Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM)

被引：22

作者：

Gay, Francesca ^{[1
]}

Cerrato, Chiara ^{[1
]}

Scalabrini, Delia Rota ^{[1
]}

Galli, Monica ^{[1
]}

Belotti, Angelo ^{[1
]}

Zamagni, Elena ^{[1
]}

Ledda, Antonio ^{[1
]}

Grasso, Mariella ^{[1
]}

Angelucci, Emanuele ^{[1
]}

Liberati, Anna Marina ^{[1
]}

Tosi, Patrizia ^{[1
]}

Pisani, Francesco ^{[1
]}

Spada, Stefano ^{[1
]}

Annibali, Ombretta ^{[1
]}

Baraldi, Anna ^{[1
]}

Omede, Paola ^{[1
]}

Galieni, Piero ^{[1
]}

Rizzi, Rita ^{[1
]}

Pescosta, Norbert ^{[1
]}

Ronconi, Sonia ^{[1
]}

Vincelli, Donatella ^{[1
]}

Cafro, Anna Maria ^{[1
]}

Offidani, Massimo ^{[1
]}

Palumbo, Antonio ^{[2
,3
]}

Musto, Pellegrino ^{[1
]}

Cavo, Michele ^{[1
]}

Boccadoro, Mario ^{[1
]}

机构：

[1] European Myeloma Network, GIMEMA, Milan, Italy

[2] Univ Torino, Turin, Italy

[3] Takeda Pharmaceut Co, Zurich, Switzerland

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-112093

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

121

引用

页数：4

共 50 条

[31] Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)
Bhutani, Manisha
Robinson, Myra
Atrash, Shebli
Watts, Nicole
Paul, Barry
Chhabra, Saurabh
Korde, Neha
Begic, Xhevahire
Foureau, David M.
Chung, David J.
Pineda-Roman, Mauricio
Koya, Brinda
Varga, Cindy
Ai, Jing
Daniels, Natonya
Norek, Sarah
Sutton, Sara A.
Anderson, Michelle B.
Jewell, Ashley N.
Eldridge, Paul W.
Acampora, Donna
Symanowski, James T.
Costa, Luciano J.
Usmani, Saad
Voorhees, Peter M.
BLOOD, 2022, 140 : 4393 - 4395
[32] Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), autologous transplantation and MRD response-adapted treatment duration and cessation in newly diagnosed Multiple Myeloma (NDMM)
Costa, Luciano
Chhabra, Saurabh
Medvedova, Eva
Dholaria, Bhagirathbhai
Schmidt, Timothy
Silbermann, Rebecca
Godby, Kelly
Dhakal, Binod
Bal, Susan
Giri, Smith
D'Souza, Anita
Cornell, Robert
Hardwick, Pamela
Omel, James
Hari, Parameswaran
Callander, Natalie S.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S33 - S33
[33] Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study
Knop, Stefan
Stuebig, Thomas
Kull, Miriam
Greil, Richard
Steiner, Normann
Bassermann, Florian
Nogai, Axel
von Lilienfeld-Toal, Marie
Janjetovic, Snjezana
Trautmann-Grill, Karolin
Bittrich, Max
Engelhardt, Monika Martha
Hoferer, Anette
Theurich, Sebastian
Binder, Mascha
Zojer, Niklas
Duerk, Heinz A.
Brueggemann, Monika
Held, Swantje
Einsele, Hermann
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[34] Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial
Jacobus, Susanna J.
Cohen, Adam D.
Weiss, Matthias
Callander, Natalie Scott
Singh, Avina A.
Parker, Terri L.
Menter, Alex R.
Yang, Xuezhong
Parsons, Benjamin Marshall
Kumar, Pankaj
Kapoor, Prashant
Rosenberg, Aaron Seth
Zonder, Jeffrey A.
Faber, Edward Anthony
Lonial, Sagar
Richardson, Paul G.
Orlowski, Robert Z.
Wagner, Lynne I.
Rajkumar, S. Vincent
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (18)
[35] Final Analysis of a Phase 2 Trial of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma (NDMM) without Autologous Stem Cell Transplantation (ASCT)
Derman, Benjamin A.
Cooperrider, Jennifer H.
Rosenblatt, Jacalyn
Avigan, David
Rampurwala, Murtuza M.
Major, Ajay
Karrison, Theodore
Jiang, Ken
Kubicki, Tadeusz
Jakubowiak, Andrzej J.
BLOOD, 2023, 142
[36] Primary Endpoint Analysis from a Response Adaptive Phase II Clinical Trial of Carfilzomib, Lenalidomide, Dexamethasone Plus Daratumumab (KRd-Dara) in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
Bhutani, Manisha
Robinson, Myra
Atrash, Shebli
Paul, Barry
Pineda-Roman, Mauricio
Foureau, David
Varga, Cindy
Friend, Reed
Begic, Xhevahire
Norek, Sarah
Drennan, Tiffany
Anderson, Michelle B.
Symanowski, James
Voorhees, Peter M.
Usmani, Saad Z.
BLOOD, 2023, 142
[37] Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial
Wester, Ruth
Zweegman, Sonja
van der Holt, Bronno
Kersten, Marie Jose
Vellenga, Edo
van Marwijk-Kooy, Marinus
Asselbergs, Emelie
de Weerdt, Okke
Minnema, Monique C.
Lonergan, Sarah
Palumbo, Antonio
Broijl, Annemiek
Sonneveld, Pieter
HEMASPHERE, 2020, 4 (04):
[38] Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
Kubicki, Tadeusz
Dytfeld, Dominik
Wrobel, Tomasz
Jamroziak, Krzysztof
Robak, Pawel
Czyz, Jaroslaw
Tyczynska, Agata
Druzd-Sitek, Agnieszka
Giannopoulos, Krzysztof
Nowicki, Adam
Szczepaniak, Tomasz
Lojko-Dankowska, Anna
Matuszak, Magdalena
Gil, Lidia
Pula, Bartosz Michal
Rybka, Justyna
Majcherek, Maciej
Usnarska-Zubkiewicz, Lidia
Szukalski, Lukasz
Konska, Agnieszka
Zaucha, Jan M.
Walewski, Jan
Mikulski, Damian
Czabak, Olga
Robak, Tadeusz
Kruk-Kwapisz, Dorota
Lahoud, Oscar Boutros
Zonder, Jeffrey A.
Griffith, Kent
Stefka, Andrew T.
Jiang, Ken
Cooperrider, Jennifer H.
Derman, Ben A.
Jakubowiak, Andrzej J.
BLOOD, 2023, 142
[39] Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma: Planned Interim Analysis of the GMMG-Concept Trial
Weisel, Katja
Besemer, Britta
Haenel, Mathias
Lutz, Raphael
Mann, Christoph
Munder, Markus
Goerner, Martin
Reinhardt, Hans Christian
Nogai, Axel
Ko, Yon-Dschun
De Wit, Maike
Salwender, Hans
Scheid, Christoph
Graeven, Ullrich
Peceny, Rudolf
Staib, Peter
Dieing, Annette
Jauch, Anna
Zago, Manola
Benner, Axel
Tichy, Diana
Bokemeyer, Carsten
Goldschmidt, Hartmut
Leypoldt, Lisa B.
BLOOD, 2022, 140 : 1836 - 1838
[40] Interim analysis of a phase 2 minimal residual disease (MRD)-adaptive trial of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) for newly diagnosed multiple myeloma (MM).
Derman, Benjamin Avi
Zonder, Jeffrey A.
Kansagra, Ankit J.
Grinblatt, David L.
Narula, Sunil
Rayani, Shayan
Stefka, Andrew T.
Jiang, Ken
Major, Sarah
Wolfe, Brittany
Whelan, Megan
Libao, Bernadette
McIver, Amanda
Andreatos, Evangelia
Juergens, Daniel
Alcantar, Luis
Karrison, Theodore
Bishop, Michael Russell
Jasielec, Jagoda
Jakubowiak, Andrzej J.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →